| Literature DB >> 35677069 |
Young-Jun Park1,2, Dora Pinto3, Alexandra C Walls1,2, Zhuoming Liu4, Anna De Marco3, Fabio Benigni3, Fabrizia Zatta3, Chiara Silacci-Fregni3, Jessica Bassi3, Kaitlin R Sprouse1, Amin Addetia1, John E Bowen1, Cameron Stewart1, Martina Giurdanella3, Christian Saliba3, Barbara Guarino3, Michael A Schmid3, Nicholas Franko5, Jennifer Logue5, Ha V Dang6, Kevin Hauser6, Julia di Iulio6, William Rivera6, Gretja Schnell6, Florian A Lempp6, Javier Janer4, Rana Abdelnabi7, Piet Maes7, Paolo Ferrari8,9,10, Alessandro Ceschi8,11,12,13, Olivier Giannini8,14, Guilherme Dias de Melo15, Lauriane Kergoat15, Hervé Bourhy15, Johan Neyts7, Leah Soriaga6, Lisa A Purcell6, Gyorgy Snell6, Sean P J Whelan4, Antonio Lanzavecchia3, Herbert W Virgin6,16,17, Luca Piccoli3, Helen Chu5, Matteo Samuele Pizzuto3, Davide Corti3, David Veesler1,2.
Abstract
SARS-CoV-2 Omicron sublineages carry distinct spike mutations and represent an antigenic shift resulting in escape from antibodies induced by previous infection or vaccination. We show that hybrid immunity or vaccine boosters result in potent plasma neutralizing activity against Omicron BA.1 and BA.2 and that breakthrough infections, but not vaccination-only, induce neutralizing activity in the nasal mucosa. Consistent with immunological imprinting, most antibodies derived from memory B cells or plasma cells of Omicron breakthrough cases cross-react with the Wuhan-Hu-1, BA.1 and BA.2 receptor-binding domains whereas Omicron primary infections elicit B cells of narrow specificity. While most clinical antibodies have reduced neutralization of Omicron, we identified an ultrapotent pan-variant antibody, that is unaffected by any Omicron lineage spike mutations and is a strong candidate for clinical development.Entities:
Year: 2022 PMID： 35677069 PMCID： PMC9176643 DOI： 10.1101/2022.05.08.491108
Source DB: PubMed Journal: bioRxiv